In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Verastem (VSTM – Research Report), with a price ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Department of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu 610041, China College of Polymer Science and Engineering, College of Biomedical Engineering, State ...

Notable updates occurred in December 2024 for investigational products in development. The table below is a review of notable updates that occurred in December 2024 for investigational products in ...

Even more fascinating is the intricate relationship between lysosomal exocytosis and focal adhesions, structures critical for cell anchoring and communication. By decoding how focal adhesions ...

Even more fascinating is the intricate relationship between lysosomal exocytosis and focal adhesions, structures critical for cell anchoring and communication. By decoding how focal adhesions ...

Defactinib is an oral, selective inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein ...

Defactinib is an oral, selective inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein ...